U.S. flag An official website of the United States government
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. The Content of Investigational Device Exemption (IDE) and Premarket Approval (PMA) Applications for Artificial Pancreas Device Systems
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

The Content of Investigational Device Exemption (IDE) and Premarket Approval (PMA) Applications for Artificial Pancreas Device Systems Guidance for Industry and Food and Drug Administration Staff November 2012

Final
Docket Number:
FDA-2011-D-0464
Issued by:
Guidance Issuing Office
Center for Devices and Radiological Health

This guidance is intended to provide recommendations to Sponsors planning to develop and submit an Investigational Device Exemption (IDE) or premarket approval (PMA) application for an Artificial Pancreas Device System (APDS) for single patient use in the home environment. For the purposes of this document, the APDS refers to low glucose suspend systems, as well as closed loop control systems. FDA recognizes the need for guidance on the least burdensome means of development for these innovative device systems. Due to the evolving nature of these device systems, it is expected that they will develop incrementally. The recommendations contained in this guidance are intended to provide adequate guidance and instruction to facilitate the development and marketing of the APDS while, at the same time, allowing sufficient flexibility to accommodate the different approaches that Sponsors may wish to take.


Submit Comments

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2011-D-0464.

 
Back to Top